公开(公告)号：WO2012145112A3

公开(公告)日：2014-05-01

申请号：PCT/US2012029791

申请日：2012-03-20

Applicant: IMMUNOGEN INC ,  FISHKIN NATHAN

Inventor： FISHKIN NATHAN

IPC: A01N43/40 ,  A61K31/435

CPC classification number: C07D498/04 ,  A61K31/5365 ,  A61K31/537 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6849 ,  C07D498/18 ,  A61K2300/00

Abstract: The invention relates to novel maytansinoid compounds having sulfoxide linkers and more specifically to novel maytansinoid compounds of structural formula (I) and (II). The invention also provides conjugates of the maytansinoid compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.

Abstract translation: 本发明涉及具有亚砜接头的新型美登木素生物化合物，更具体地涉及结构式（I）和（II）的新型美登木素生物碱化合物。 本发明还提供与细胞结合剂连接的美登木素生物碱化合物的缀合物。 本发明还提供了使用本发明的化合物或缀合物来抑制哺乳动物异常细胞生长或治疗增殖性病症的组合物和方法。

公开(公告)号：WO2013149171A3

公开(公告)日：2013-11-21

申请号：PCT/US2013034646

申请日：2013-03-29

Applicant: IMMUNOGEN INC

Inventor： CARRIGAN CHRISTINA N

IPC: G01N33/53 ,  G01N33/48 ,  G01N33/58

CPC classification number: G01N33/574 ,  C07K16/2896 ,  C07K2317/76 ,  G01N33/57407 ,  G01N33/57426 ,  G01N33/57492 ,  G01N2333/70596 ,  G01N2800/52

Abstract: Methods to improve the success of cancer therapies that target CD37 are provided. Kits comprising reagent useful in the methods are further provided.

Abstract translation: 提供了提高靶向CD37的癌症治疗成功的方法。 还提供了包含在该方法中有用的试剂的试剂盒。

公开(公告)号：WO2013078271A1

公开(公告)日：2013-05-30

申请号：PCT/US2012/066205

申请日：2012-11-21

Applicant: IMMUNOGEN, INC.

Inventor： SETIADY, Julianto ,  PARK, Peter, U. ,  CHITTENDEN, Thomas

IPC: A61P35/00 ,  A61K38/00 ,  A61K39/00 ,  A61K39/395

CPC classification number: A61K47/48369 ,  A61K39/39558 ,  A61K47/6803 ,  A61K47/6851 ,  A61K2039/505 ,  C07K16/2863 ,  C07K2317/24

Abstract: The present invention relates to the identification that EGFR antibody immunoconjugates are effective in inhibiting the growth of tumor ceils that have developed EGFR and/or ALK resistance mechanisms. Methods of administering the EGFR antibody immunoconjugates to patients having resistant toner cells is also disclosed.

Abstract translation: 本发明涉及EGFR抗体免疫缀合物有效抑制已经发展为EGFR和/或ALK抗性机制的肿瘤细胞生长的鉴定。 还公开了向具有抗性调色剂细胞的患者施用EGFR抗体免疫偶联物的方法。

公开(公告)号：WO2012149412A2

公开(公告)日：2012-11-01

申请号：PCT/US2012035582

申请日：2012-04-27

Applicant: IMMUNOGEN INC ,  GUIDI CYNTHIA J ,  ZHOU XIAO-MAI ,  ZHANG CHONGHUI ,  TAVARES DANIEL ,  PARK PETER

Inventor： GUIDI CYNTHIA J ,  ZHOU XIAO-MAI ,  ZHANG CHONGHUI ,  TAVARES DANIEL ,  PARK PETER

IPC: A61K47/48 ,  A61K39/395

CPC classification number: F16B17/00 ,  A61K47/48384 ,  A61K47/48561 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  A61K2300/00 ,  C07K16/22 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: Novel therapeutic and diagnostic agents, including, but not limited to, antibodies and immunoconjugates, that bind to endoglin (CD105) are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth, as well as an animal model for testing such agents, are further provided.

Abstract translation: 提供了结合内皮糖蛋白（CD105）的新型治疗和诊断剂，包括但不限于抗体和免疫缀合物。 还提供了使用试剂，抗体或免疫缀合物的方法，例如抑制肿瘤生长的方法，以及用于测试这些试剂的动物模型。

公开(公告)号：WO2012112687A1

公开(公告)日：2012-08-23

申请号：PCT/US2012/025257

申请日：2012-02-15

Applicant: IMMUNOGEN, INC. ,  FISHKIN, Nathan ,  MILLER, Michael ,  LI, Wei ,  SINGH, Rajeeva

Inventor： FISHKIN, Nathan ,  MILLER, Michael ,  LI, Wei ,  SINGH, Rajeeva

IPC: A61K47/48 ,  C07D487/04 ,  C07D519/00 ,  A61P35/00

CPC classification number: C07K16/30 ,  A61K31/5517 ,  A61K45/06 ,  A61K47/545 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6867 ,  A61K2039/505 ,  C07D487/04 ,  C07D519/00 ,  C07K2317/24 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention is directed to methods of preparing a conjugate of a cell-binding agent and a drug (such as a cytotoxic compound). The methods comprise the use of an imine reactive compound to enable efficient conjugations of cytotoxic compounds with cell binding agents.

Abstract translation: 本发明涉及制备细胞结合剂和药物（例如细胞毒性化合物）的缀合物的方法。 所述方法包括使用亚胺反应性化合物以使细胞毒性化合物与细胞结合剂的有效缀合。

公开(公告)号：WO2012058592A2

公开(公告)日：2012-05-03

申请号：PCT/US2011/058385

申请日：2011-10-28

Applicant: IMMUNOGEN, INC. ,  SETIADY, Julianto ,  SINGH, Rajeeva ,  PARK, Peter, U. ,  RUI, Lingyun ,  CHITTENDEN, Thomas

Inventor： SETIADY, Julianto ,  SINGH, Rajeeva ,  PARK, Peter, U. ,  RUI, Lingyun ,  CHITTENDEN, Thomas

IPC: A61K39/395

CPC classification number: C07K16/40 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6871 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/30 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/74 ,  G01N2333/71 ,  G01N2333/912

Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.

Abstract translation: 提供了与EGFR结合的新型抗癌剂，包括但不限于抗体和免疫偶联物。 还提供了使用试剂，抗体或免疫缀合物的方法，例如抑制肿瘤生长的方法。

公开(公告)号：WO2012019024A3

公开(公告)日：2012-02-09

申请号：PCT/US2011/046624

申请日：2011-08-04

Applicant: IMMUNOGEN, INC. ,  SETIADY, Julianto ,  SKALETSKAYA, Anna ,  RUI, Lingyun ,  TAVARES, Daniel ,  PARK, Peter

Inventor： SETIADY, Julianto ,  SKALETSKAYA, Anna ,  RUI, Lingyun ,  TAVARES, Daniel ,  PARK, Peter

IPC: C07K16/32 ,  A61K47/48 ,  A61P35/00 ,  A61K39/395

Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to HER3 are provided. Methods of using the HER3-binding agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth, are further provided.

公开(公告)号：WO2011091286A1

公开(公告)日：2011-07-28

申请号：PCT/US2011/022103

申请日：2011-01-21

Applicant: IMMUNOGEN, INC. ,  WHITEMAN, Kathleen, R. ,  O'LEARY, James, J. ,  LUTZ, Robert, John

Inventor： WHITEMAN, Kathleen, R. ,  O'LEARY, James, J. ,  LUTZ, Robert, John

IPC: C07K16/00 ,  C07K17/00 ,  C07K17/14

CPC classification number: C07K16/2803 ,  A61K2039/505

Abstract: The present invention relates to surprisingly effective anti-cancer drug combinations, pharmaceutical compositions comprising the same, and uses thereof in the treatment of ovarian cancer. In particular, the present invention is based on the discovery that the administration of a CD56 antibody linked to a cytotoxic compound ( e.g. , an immunoconjugate) in combination with at least two chemotherapeutic agents (in particular a taxane compound and a platinum compound), improves the therapeutic index in the treatment of ovarian cancer over and above the additive effects of the anticancer agents used alone. In one embodiment of the invention, combinations of the CD56 antibody, or fragment thereof, linked to a cytotoxic compound plus additional chemotherapeutic agents have a synergistic effect in the ovarian cancer therapeutic index. The present invention also provides methods of modulating the growth of selected cell populations, such as ovarian cancer cells, by administering a therapeutically effective amount of such combinations.

Abstract translation: 本发明涉及惊人的有效的抗癌药物组合，包含其的药物组合物及其在治疗卵巢癌中的用途。 特别地，本发明是基于以下发现：与至少两种化学治疗剂（特别是紫杉烷化合物和铂化合物）组合施用与细胞毒性化合物（例如，免疫偶联物）连接的CD56抗体改善 治疗卵巢癌的治疗指标超过单独使用的抗癌剂的加和效应。 在本发明的一个实施方案中，与细胞毒性化合物加上其他化学治疗剂连接的CD56抗体或其片段的组合在卵巢癌治疗指数中具有协同作用。 本发明还提供了通过施用治疗有效量的这种组合来调节所选细胞群体如卵巢癌细胞的生长的方法。

公开(公告)号：WO2010128087A3

公开(公告)日：2011-01-27

申请号：PCT/EP2010056124

申请日：2010-05-05

Applicant: BIOTEST AG ,  IMMUNOGEN INC ,  OSTERROTH FRANK ,  UHEREK CHRISTOPH ,  BRUECHER CHRISTOPH ,  DAELKEN BENJAMIN ,  ENGLING ANDRE ,  HAEDER THOMAS ,  WARTENBERG-DEMAND ANDREA ,  NIEMANN GABRIELE ,  ZUBER CHANTAL ,  CZELOTH NIKLAS ,  AIGNER SILKE ,  ZENG STEFFEN

Inventor： OSTERROTH FRANK ,  UHEREK CHRISTOPH ,  BRUECHER CHRISTOPH ,  DAELKEN BENJAMIN ,  ENGLING ANDRE ,  HAEDER THOMAS ,  WARTENBERG-DEMAND ANDREA ,  NIEMANN GABRIELE ,  ZUBER CHANTAL ,  CZELOTH NIKLAS ,  AIGNER SILKE ,  ZENG STEFFEN

IPC: A61K47/48 ,  A61P35/00

CPC classification number: A61K47/48276 ,  A61K47/6425 ,  A61K47/66 ,  A61K47/6851 ,  B82Y5/00

Abstract: Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination.

Abstract translation: 公开的方法和治疗方案包括施用靶向CD138的免疫接种物来对抗疾病。 免疫缀合物既可用作单一活性成分，也可用作治疗方案的一部分或作为抗癌组合的一部分。

公开(公告)号：WO2010126552A1

公开(公告)日：2010-11-04

申请号：PCT/US2009/059661

申请日：2009-10-06

Applicant: IMMUNOGEN, INC. ,  CHARI, Ravi, V., J.

Inventor： CHARI, Ravi, V., J.

IPC: A61K39/00 ,  C07D225/04 ,  C07D487/00

CPC classification number: C07K16/2803 ,  C07D498/18 ,  C07K16/30 ,  C07K2317/73

Abstract: The present invention relates to the use of about 2 to about 8 drug molecules, for example, maytansinoid, per cell binding agent, such as an antibody, and maximal efficacy as compared to a drug load of lesser or higher number of drugs linked to such a cell binding agent.

Abstract translation: 本发明涉及使用约2至约8种药物分子，例如美登木素生物碱，每种细胞结合剂，例如抗体，以及与药物负载量相关的较小或更高数量的药物相比，具有最大功效 细胞结合剂。